AR004014A1 - Una composicion antibacteriana de cefditoren pivoxilo para administracion oral y metodo para obtener dicha composicion - Google Patents

Una composicion antibacteriana de cefditoren pivoxilo para administracion oral y metodo para obtener dicha composicion

Info

Publication number
AR004014A1
AR004014A1 ARP960104719A ARP960104719A AR004014A1 AR 004014 A1 AR004014 A1 AR 004014A1 AR P960104719 A ARP960104719 A AR P960104719A AR P960104719 A ARP960104719 A AR P960104719A AR 004014 A1 AR004014 A1 AR 004014A1
Authority
AR
Argentina
Prior art keywords
composition
water
oral administration
cefditoren pivoxil
cefditoren
Prior art date
Application number
ARP960104719A
Other languages
English (en)
Original Assignee
Meiji Seika Kaisha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Kaisha filed Critical Meiji Seika Kaisha
Publication of AR004014A1 publication Critical patent/AR004014A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se provee ahora una composición antibacteriana de Cefditoren pivoxilo para ser utilizada en forma de administración oral y que tiene un reducido gustoamargo y una acrecentada dispersibilidad en el agua, composición que comprende una mezcla deCefdi toren pivoxilo con una porción de una sal de caseínasoluble en el agua. También se provee una composición antibacteriana de Cefditoren pivoxilo para ser utilizada en forma de administración oral y quetiene un gusto amargo reducido yuna acrec entada dispersibilidad y que también es capaz de mantener un elevado índice de disolución de Cefditoren pivoxilo enel agua aún después de un almacenamiento a elevada temperatura, composición que comprende una mezcla de Cefditoren pivoxilocon una po rción de una sal decaseína soluble en agua y con una porción de una sal de ácido polifosfórico farmacéuticamente aceptable y soluble en agua.
ARP960104719A 1995-10-13 1996-10-11 Una composicion antibacteriana de cefditoren pivoxilo para administracion oral y metodo para obtener dicha composicion AR004014A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP26584795 1995-10-13

Publications (1)

Publication Number Publication Date
AR004014A1 true AR004014A1 (es) 1998-09-30

Family

ID=17422903

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960104719A AR004014A1 (es) 1995-10-13 1996-10-11 Una composicion antibacteriana de cefditoren pivoxilo para administracion oral y metodo para obtener dicha composicion

Country Status (16)

Country Link
US (1) US5958915A (es)
EP (1) EP0862915B1 (es)
KR (1) KR100311576B1 (es)
CN (1) CN1102046C (es)
AR (1) AR004014A1 (es)
AT (1) ATE214930T1 (es)
BR (1) BR9610836A (es)
CA (1) CA2234426C (es)
DE (1) DE69620220T2 (es)
ES (1) ES2174109T3 (es)
HK (1) HK1016477A1 (es)
HU (1) HU224922B1 (es)
MX (1) MX9802849A (es)
PT (1) PT862915E (es)
TW (1) TW458778B (es)
WO (1) WO1997013516A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2393972T3 (es) * 1998-01-07 2013-01-03 Meiji Seika Kaisha, Ltd. Composiciones de cefalosporina amorfa, cristalográficamente estable y procedimiento de preparación de las mismas
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
IL142896A0 (en) * 1998-11-02 2002-04-21 Elan Corp Plc Multiparticulate modified release composition
JP4827367B2 (ja) * 2000-11-21 2011-11-30 杏林製薬株式会社 ドライシロップ剤
EP1364643A4 (en) * 2000-12-01 2009-07-15 Kyowa Hakko Kogyo Kk COMPOSITION WITH IMPROVED ORAL SOLUBILITY OR ABSORBABILITY
JP5051865B2 (ja) 2001-05-29 2012-10-17 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド レシチンでのプロドラッグエステル非乳化調合物の経口バイオアベイラビリティの向上
US20030060451A1 (en) * 2001-05-29 2003-03-27 Rajneesh Taneja Enhancement of oral bioavailability of non-emulsified formulations of prodrug esters with lecithin
AU2003235395A1 (en) * 2002-05-22 2003-12-02 Shionogi And Co., Ltd. Pharmaceutical preparation improved in dissolving property of drug slightly soluble in water
AUPS303202A0 (en) * 2002-06-20 2002-07-11 Pacific Biolink Pty Limited Protein based oral lubricant
CA2500712C (en) * 2002-10-02 2011-08-09 Meiji Seika Kaisha, Ltd. Antibiotic pharmaceutical composition with improved oral absorbability
EP1671635B1 (en) * 2003-10-08 2012-01-04 Meiji Seika Pharma Co., Ltd. Noncrystalline antibacterial composition containing cefditoren pivoxil
JP2005162696A (ja) * 2003-12-04 2005-06-23 Nichiko Pharmaceutical Co Ltd 溶出性に優れたセフジトレンピボキシル製剤
DE602005023509D1 (de) * 2004-11-16 2010-10-21 3M Innovative Properties Co Dentalfüllstoffe, verfahren, zusammensetzungen mit einem caseinat
EP2832342A3 (en) 2004-11-16 2015-02-11 3M Innovative Properties Company of 3M Center Dental compositions with calcium phosphorus releasing glass
CA2587275A1 (en) 2004-11-16 2006-05-26 3M Innovative Properties Company Dental fillers and compositions including phosphate salts
CA2587556A1 (en) 2004-11-16 2006-05-26 3M Innovative Properties Company Dental fillers including a phosphorus containing surface treatment, and compositions and methods thereof
DE112006001606T5 (de) 2005-06-08 2009-07-09 Elan Pharma International Ltd., Athlone Nanopartikuläre und eine kontrollierte Freisetzung aufweisende Zusammensetzung, die Cefditoren umfassen
US20080069879A1 (en) * 2006-05-02 2008-03-20 Ravishekhar Bhiwgade Stable solid dosage form containing amorphous cefditoren pivoxil and process for preparation thereof
WO2010068359A1 (en) 2008-12-11 2010-06-17 3M Innovative Properties Company Surface-treated calcium phosphate particles suitable for oral care and dental compositions
TR201000688A2 (tr) * 2010-01-29 2011-08-22 B�Lg�� Mahmut Aktif madde olarak sefaklor ve klavulanik asit içeren efervesan formülasyonlar.
US20130143857A1 (en) * 2010-07-23 2013-06-06 Lupin Limited Pharmaceutical compositions of cefditoren pivoxil
WO2016114727A1 (en) 2015-01-16 2016-07-21 Öğün Yusuf Toktamiş Cefditoren pivoxil compositions with improved stability and production methods thereof
CN105663058A (zh) * 2016-02-01 2016-06-15 济南康和医药科技有限公司 一种头孢妥仑匹酯纳米粒药物制剂及制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5936609A (ja) * 1982-08-26 1984-02-28 Nitto Electric Ind Co Ltd 粘着性貼付製剤
JPS59184122A (ja) * 1983-03-31 1984-10-19 Nitto Electric Ind Co Ltd アクリル系膏体
JPS60102168A (ja) * 1983-11-08 1985-06-06 Tsukishima Shokuhin Kogyo Kk エイコサペンタエン酸強化乳化物及び食品の製造方法
IE58487B1 (en) * 1984-09-07 1993-09-22 Kaisha Maiji Seika New cephalosporin compounds and the production thereof
JPH0678234B2 (ja) * 1988-04-19 1994-10-05 明治製菓株式会社 経口投与用抗菌組成物
JPH0635394B2 (ja) * 1989-02-28 1994-05-11 雪印乳業株式会社 薬物の溶解性および吸収性の改善方法
JPH0717866A (ja) * 1993-06-16 1995-01-20 Meiji Seika Kaisha Ltd 医薬組成物
JPH0840907A (ja) * 1994-08-03 1996-02-13 Meiji Seika Kaisha Ltd セファロスポリン注射剤

Also Published As

Publication number Publication date
CA2234426A1 (en) 1997-04-17
HUP9900609A3 (en) 2001-04-28
DE69620220T2 (de) 2002-11-28
CA2234426C (en) 2003-07-08
CN1102046C (zh) 2003-02-26
ES2174109T3 (es) 2002-11-01
HK1016477A1 (en) 1999-11-05
DE69620220D1 (de) 2002-05-02
WO1997013516A1 (fr) 1997-04-17
CN1202110A (zh) 1998-12-16
KR100311576B1 (ko) 2001-12-28
MX9802849A (es) 1998-11-30
EP0862915A1 (en) 1998-09-09
KR19990064137A (ko) 1999-07-26
HU224922B1 (en) 2006-04-28
EP0862915B1 (en) 2002-03-27
EP0862915A4 (en) 1998-11-11
ATE214930T1 (de) 2002-04-15
TW458778B (en) 2001-10-11
BR9610836A (pt) 1999-07-13
US5958915A (en) 1999-09-28
HUP9900609A2 (hu) 1999-07-28
PT862915E (pt) 2002-09-30

Similar Documents

Publication Publication Date Title
AR004014A1 (es) Una composicion antibacteriana de cefditoren pivoxilo para administracion oral y metodo para obtener dicha composicion
SE9503143D0 (sv) New preparation
AR025427A1 (es) Formas farmaceuticas de administracion oral al menos parcialmente retardadas cuya sustancia activa tramadol se encuentra al menos parcialmente en forma decompuesto formado in situ con una hidrosolubilidad < o = 100 mg/ml, y procedimiento para su preparacion
CA2260852A1 (en) Pleasant-tasting aqueous liquid composition of a bitter-tasting drug
BR9611523A (pt) Meios de administração para drogas analgésicas, antiinflamatórias e antipiréticas contendo óxido nitroso e composições farmacêuticas contendo tais meios e drogas.
MY116124A (en) Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug
AR017512A1 (es) Tabletas de metilcelulosa rapidamente desintegrables para administracion por via oral y procedimiento para prepararlas
DE69925251D1 (de) Zusammensetzungen enthaltend isovalerianamide zusammen mit ibuprofen
ZA894828B (en) Process for the preparation of anti-inflammatory pharmaceutical agents with an ibuprofen base,with elimination,in solution,of the bitter taste,burning of the throat and intestinal toxicity
HK1058622A1 (en) Pharmaceutical form of administration for peptides, method for its production and use
ES2109131B1 (es) Composicion farmaceutica que tiene actividad analgesica.
TW354256B (en) A pharmaceutical composition for oral consumption in aqueous solution comprising a drug/<beta>-cyclodextrin complex and a pharmaceutically acceptable acid-base couple
ES2142430T3 (es) Compuestos farmaceuticos en forma de gel conteniendo sales de sulfato de condroitina apropiadas para administracion oral.
WO2004071156A3 (en) Use of edible acid in fast-dispersing pharmaceutical solid dosage forms
CA2477773A1 (en) A stable diclofenac-tromethamine composition for the topical treatment of oropharyngeal cavity disorders
ATE249224T1 (de) Oxytetracyclin enthaltendes arzneimittel mit verzögerter wirksoffabgabe
ZA951588B (en) Antitussive composition
MXPA02011832A (es) Manejo del ronquido por medio de la administracion oral de dimetilsulfona.
WO1991018606A3 (en) Orally active nonaddicting analgesics
CO5640085A2 (es) Formulaciones farmaceuticas que comprenden amoxicilina y clavulanato
WO1999047172A3 (en) Oral pharmaceutical compositions to be taken without liquids, which contain inclusion complexes
JP2002537246A5 (es)
CO5070673A1 (es) Composiciones farmaceuticas en forma de solucion estable que comprenden (1s,4r)-cis-4-(2-amino-6-(ciclopropilamino)-9h -purin-9-il)-2-ciclopenteno-1-metanol, un quelador de metal y un agente endulzante
GB1475861A (en) Pharmaceutical composition
DK0927031T3 (da) Farmaceutisk sammensætning indeholdende nimesulid til oral admnistration

Legal Events

Date Code Title Description
FG Grant, registration